Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale

NCT01526785 is registered in ClinicalTrials.gov with Genzyme, a Sanofi Company as lead sponsor.

NCT NCT01526785
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01526785 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4 Open Label, Prospective Study in Patients With Pompe Disease to Evaluate The Efficacy and Safety of Alglucosidase Alfa Produced at the 4000L Scale
Lead sponsor
Genzyme, a Sanofi Company
Phase
Phase 4
Overall status
Terminated
Start date
March 31, 2012
Completion date
December 31, 2014
Enrollment
113 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

pompe disease